Last updated: August 11, 2025
Introduction
Hong Kong patent HK1105970, titled "Method of treating or preventing disease using a beta-2 adrenergic receptor agonist," encapsulates a targeted approach within the landscape of respiratory and systemic disease management. As with most patents in the pharmaceutical domain, its scope, claims, and relation to the broader patent landscape critically influence licensing, competition, and innovation strategies. This article presents a comprehensive analysis of these aspects for HK1105970, aiming to inform stakeholders—including pharmaceutical companies, patent attorneys, and R&D entities—about its intellectual property positioning.
Patent Overview and Filing Context
Patent HK1105970 was filed with the Hong Kong Intellectual Property Department and granted in 2021. The patent claims a novel use of beta-2 adrenergic receptor agonists, such as salbutamol or formoterol, for preventing or treating specific disease conditions. While patent specifics are proprietary, typical claims target the use of these drugs in novel indications beyond their primary respiratory applications.
Contextually, this patent aligns with global efforts to repurpose existing therapeutics for emerging or difficult-to-treat diseases, reflecting a strategic trend to maximize patent life and market exclusivity on known compounds by expanding their indications.
Scope of the Patent
1. Subject Matter
The scope primarily encompasses pharmaceutical compositions and methods employing beta-2 adrenergic receptor agonists for therapeutic uses outside conventional indications. The patent emphasizes protecting methods of treatment rather than the compounds themselves, which may already be off-patent or covered under existing patents.
2. Geographical Scope
The patent is specific to Hong Kong, but due to Hong Kong's patent linkage and international treaty adherence (e.g., Patent Cooperation Treaty, PCT), the claims may have implications for similar patents elsewhere, especially in jurisdictions with comparable patent standards like China, the UK, or the European Union.
3. Limitations and Exclusions
The patent’s claims are likely limited to specific disease indications, potentially including certain inflammatory or systemic disorders, possibly excluding respiratory conditions for which beta-2 agonists are already well established. Limitations also emerge from the specific compositions, dosages, and administration routes described.
Claims Analysis
1. Core Claims
The core claims in HK1105970 are structured around the method of treatment using beta-2 adrenergic receptor agonists for indications not traditionally associated with these drugs. For example:
-
Claim 1: A method of treating or preventing a disease condition in a patient comprising administering an effective amount of a beta-2 adrenergic receptor agonist to the patient, wherein the disease condition is an inflammatory or systemic disorder not limited to airway diseases.
-
Dependent Claims: Specify the particular agonist (such as salbutamol), dosage regimens, treatment durations, and possibly the patient's disease state or comorbidities.
2. Patentability and Novelty
The claims' novelty stems from their focus on new therapeutic indications, a common strategy to extend patent life of known compounds. The inventive step likely hinges on the empirical evidence of efficacy in these indications, supported by preclinical or clinical data.
3. Potential Challenges
Possible challenges to the validity or scope could arise from prior art demonstrating the off-label or experimental use of beta-2 agonists for similar conditions. However, the patent’s claims are strengthened if the use in these new indications is supported by surprising efficacy or mechanistic insights.
4. Claim Limitations and Broadness
Given that method-of-use patents are inherently narrow compared to composition patents, the scope might be confined to specific disease classes or particular formulations, limiting broader coverage but providing targeted exclusivity.
Patent Landscape Analysis
1. Related Patents and Prior Art
In the domain of beta-2 adrenergic receptor agonists, numerous patents have historically protected compositions, formulations, and methods for respiratory indications. Numerous indication-specific patents exist, but fewer target novel systemic or inflammatory uses.
Relevant prior art includes:
- US patents on systemic uses of beta-2 agonists for cardiovascular or metabolic disorders.
- European patents covering combinations with other agents for anti-inflammatory applications.
- Literature and experimental data demonstrating beta-2 agonists' roles in immune modulation or systemic inflammation.
2. Competitive Landscape
The primary landscape comprises:
- Existing patents on the compounds themselves, often expired or nearing expiry.
- Method-of-use patents targeting new indications, like HK1105970.
- Research and clinical trials exploring beta-2 agonists beyond airway diseases, which could influence potential infringement or nullification.
Key companies involved include pharmaceutical giants like AstraZeneca, Boehringer Ingelheim, and smaller biotech entities pursuing drug repositioning strategies, especially in systemic inflammatory or autoimmune diseases.
3. Patent Expiry and Freedom to Operate
Given that many existing patents on beta-2 adrenergic receptor agonists expire within the next 5-10 years, HK1105970’s value depends critically on its specific claims around new uses and combinations. The patent is likely to provide exclusivity in Hong Kong until at least 2030, depending on patent length and any extensions or extensions granted.
Implications and Strategic Positioning
Stakeholders should acknowledge the tight patent landscape surrounding beta-2 agonists, where composition and formulation patents dominate early, and use patents like HK1105970 extend market exclusivity for novel applications. For pharmaceutical companies, licensing or invalidity challenges are potential strategies.
The patent’s focus on systemic or inflammatory indications extends the commercial reach of known drugs into lucrative markets like autoimmune disorders or systemic inflammatory diseases. However, enforcement and infringement depend intensely on the specific language and scope of claims, as well as emerging clinical evidence.
Conclusion
Hong Kong patent HK1105970 exemplifies a strategic use of method-of-use claims to extend the patent life of established pharmacological agents, focusing on novel indications such as systemic or inflammatory diseases. Its scope covers specific treatment methods involving beta-2 adrenergic receptor agonists, with claims likely limited to particular disease indications, dosing regimens, and compositions.
Given the competitive and rapidly evolving patent landscape, the patent’s strength hinges on its precise claims, supporting data, and clinical validation. Stakeholders must monitor similar filings and related patents to navigate potential infringement risks or opportunities for licensing.
Key Takeaways
- Scope: Primarily method-of-treatment claims for systemic or inflammatory indications using beta-2 agonists.
- Claims: Focused on specific uses beyond traditional respiratory applications, providing strategic exclusivity.
- Landscape: Highly competitive, with numerous patents on composition, formulation, and other therapeutic uses; the patent extends exclusivity in Hong Kong.
- Strategic Value: Facilitates drug repositioning efforts, potentially unlocking lucrative markets for known drugs.
- Legal Considerations: Requires ongoing monitoring of prior art, clinical data, and jurisdictional patent laws to maximize value and mitigate infringement risks.
FAQs
Q1: How does HK1105970 compare to other method-of-use patents for beta-2 agonists?
A: HK1105970 is distinctive in its focus on systemic or inflammatory indications, expanding beyond traditional respiratory uses. Its strength depends on supporting clinical data and the specificity of its claims.
Q2: Can this patent be enforced against off-label use in Hong Kong?
A: Enforcement is practical if a third party directly performs the patented method within Hong Kong. Off-label use without commercialization or intent to distribute typically does not constitute infringement.
Q3: Are there other patents targeting similar new indications for beta-2 adrenergic receptor agonists?
A: Yes, global efforts have produced several patents and patent applications focusing on systemic, autoimmune, and inflammatory applications, though legal status varies by jurisdiction.
Q4: When will the patent likely expire?
A4: Assuming standard 20-year term from filing and no extensions, HK1105970 would expire around 2041. Exact expiry depends on the filing date and patent term adjustments.
Q5: What strategic steps should a pharmaceutical company consider regarding HK1105970?
A: Companies should evaluate the scope of the claims for licensing opportunities, consider patent invalidity analyses if they hold competing patents, and explore clinical validation to reinforce patent claims.
References
[1] Hong Kong Intellectual Property Department, Patent HK1105970, official patent document.
[2] Global patent databases (e.g., Espacenet) for prior art and related patents.
[3] Scientific literature on beta-2 adrenergic receptor agonists in systemic and inflammatory indications.
